April 6 Quick Takes: MGH to pilot AZ digital platform; plus NorthShore-GoPath prostate cancer risk test, baricitinib delay at FDA, MTEM setback
AstraZeneca plc (LSE:AZN; NASDAQ:AZN) partnered with Massachusetts General Hospital to test the pharma’s AMAZE digital disease management platform in real-world studies of heart failure and asthma patients. The MGH Center for Innovation in Digital Healthcare will lead the pilot of the platform, which includes a patient app and clinician dashboard, with the goals of improving patient engagement, clinical care-team communication and outcomes while cutting healthcare costs.
NorthShore, GoPath launch polygenic risk score-based prostate cancer risk test
NorthShore University HealthSystem and GoPath Laboratories LLC launched a prostate cancer risk test that incorporates family history, rare pathogenic mutations and a genetic risk score described in a European Urology study that is based on more than 100 prostate cancer risk-associated SNPs. The partners said the test is more applicable to men of different races, including Black men, than existing marketed tests...